OUTCOME OF HIGH DOSE CHEMOTHERAPY PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION (HDT‐ASCT) IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: EXPERIENCE OF A SINGLE ITALIAN INSTITUTION

Introduction: Patients (pts) with follicular lymphoma (FL) can have long survival, nevertheless most of them subsequent relapses disease-free intervals progressively shorter. In the present chemo-free era role transplantation has been questioned and its right place in treatment plan relapse/refractory (R/R) disease is still challenging. The aim this analysis was to collect long-term follow-up data on pts treated HDT-ASCT our Institution focusing outcome toxicity. Methods: All patients R/R FL, consecutively last 18 years were considered. Response assessment made as recommended by International Workshop criteria survival calculated Kaplan-Meyer method. primary end point overall (OS). Secondary points included progression-free (PFS), time progression (TTP), second tumors. Survival also focused different subgroups divided according early (POD24) or late (noPOD24) relapse timing transplant procedure. Results: Between June 2003 May 2021, 87 underwent ASCT, 70 had complete be considered for analysis. Median age 58 yrs (range 37–75) 53% (POD24). With a median 110 months from ASCT 4–197), 5-years(yrs) 10-yrs OS 80% 69%, PFS 55% 39% TTP 62% 51% respectively, plateau around 8 after (Figure 1). No difference recorded receiving line (80%) later (20%). cohort 45 transplanted 2nd-line who received 1st-line therapy within first year diagnosis, 10 versus 79% (p = 0.26) POD24 noPOD24, respectively. Transplant Related Mortality observed. Thirty (43%) progression, 2, (3%) histological transformation into diffuse large B-cell lymphoma. Nineteen (27%) developed 2nd tumors [10 (53%) hematological, (42%) solid 1 (5%) both]. majority (84%) previously purine analogues Ibritumomab tiuxetan both. Twenty (29%) died [4 (20%) lymphoma, 12 (60%) 4 infections including 3 covid-19]. Keyword: indolent non-Hodgkin conflicts interests pertinent abstract.